EU Science and Ethics Advisors Urge Independent AI Evaluation as U.S. FDA Adopts Super Intelligence Terminology
The European Commission Group of Chief Scientific Advisors and the European Group on Ethics issued a joint statement calling for independent public model evaluation, while the U.S. FDA implemented Executive Order 14434 terminology rules effective November 16, 2026.
By 全球伯乐 News
Source compilation
On this page
Transatlantic governance of advanced computing systems diverged between substantive oversight capacity and administrative nomenclature on November 16, 2026. The European Commission Directorate-General for Research and Innovation published a rare joint statement by the Group of Chief Scientific Advisors (GCSA) and the European Group on Ethics in Science and New Technologies (EGE) urging independent European model evaluation capacity1, while the U.S. Food and Drug Administration (FDA) announced that its public-facing documents would transition to the terms "Super Intelligence" and "SI" beginning November 16 under Executive Order 144342.

AI-generated editorial illustration: a clear optical glass prism block, a minimalist brushed-brass balance beam arm, and a satin-aluminum precision hinge on a dark basalt slab represent European independent AI model evaluation safeguards and U.S. federal regulatory terminology alignment, not a real European Commission or FDA office photograph.
European Advisors Warn Against Delegating Model Safety Evaluation to Commercial Developers
Although the seven-member Group of Chief Scientific Advisors and the European Group on Ethics have previously issued separate opinions on artificial intelligence in scientific research, crisis management, and neuro-technology governance, their joint statement—titled The Next Phase of Artificial Intelligence: Governing for Safety, Security and Human Agency—marks an unusual coordinated intervention. The advisors warn that as autonomous and general-purpose systems become deeply embedded across critical data processing and public administration, traditional regulatory guardrails no longer suffice. They caution that insufficient institutional enforcement capacity or external pressure to delay or dilute European legislation could erode public safeguards1.
To prevent regulatory lag, the two advisory bodies set out four core recommendations anchored in the EU Artificial Intelligence Act (Regulation (EU) 2024/1689), the 2025 General-Purpose AI Code of Practice, and the proposed Cloud and AI Development Act (COM(2026) 502 final). First, safety, security, and meaningful human agency must remain non-negotiable prerequisites for system deployment. Second, the pace of model development and rollout should be calibrated directly to verified degrees of potential harm. Third, the European Union must build its own independent technical capacity to evaluate frontier models rather than delegating safety assessments to commercial developers. Fourth, regulators should establish a continuous-learning evaluation ecosystem whose empirical testing methodologies evolve in lockstep with model capabilities1.
FDA Clarifies Executive Order 14434 Scope and Preserves Statutory Filing Standards
In the United States, the Food and Drug Administration detailed how federal medical product oversight will implement Executive Order 14434, Inaugurating the Era of Super Intelligence, signed on September 29, 2026. Section 3(a) of the directive instructs federal executive departments and agencies, to the maximum extent permitted by law, to replace "Artificial Intelligence" and "AI" with "Super Intelligence" and "SI" across official correspondence, websites, reports, and non-statutory policy documents, while tying the definition directly to the existing statutory scope of artificial intelligence under 15 U.S.C. 9401(3)2.
Beginning November 16, 2026, newly issued public-facing FDA communications adopt the "Super Intelligence" and "SI" terminology, whereas existing guidance documents, Federal Register notices, electronic submission templates, and regulatory databases will be updated gradually during scheduled maintenance cycles or future substantive revisions. Crucially for regulated industries across pharmaceuticals, biologics, medical devices, food, and veterinary products, the agency confirmed that existing rules and guidance remain in full effect as written, statutory citations to "artificial intelligence" will continue to be quoted verbatim, and the executive order imposes no new obligations on sponsors, applicants, or manufacturers regarding established product names, trade names, or labeling2.
Source notes
-
2026-11-16 · AI requires rigorous safeguards and rules that keep pace with technological advances– experts tell the European Commission · European Commission Directorate-General for Research and Innovation. ↩ ↩2 ↩3
-
2026-11-16 · FDA's Use of “Super Intelligence” and “SI” Under Executive Order 14434 · U.S. Food and Drug Administration (FDA). ↩ ↩2 ↩3


